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Ceramides are the most abundant lipids constituting
the intercellular matrix of the skin stratum corneum
and their critical role in skin homeostasis has been
extensively documented. Their concentration in the
skin highly depends on the rate of availability of the
enzymes involved in ceramide generation. The aim
of this study was to investigate whether the concen-
tration of prosaposin was altered in the skin of
patients with psoriasis vulgaris. Prosaposin, the pre-
cursor of saposins (sphingolipid activator proteins),
was measured in lesional and nonlesional skin of
psoriatic patients and in normal skin from surgical
patients, both at the mRNA and at the protein
level. Densitometric analysis of reverse transcriptase±
polymerase chain reaction bands separated by gel-
electrophoresis showed a progressive decrease of
prosaposin mRNA expression in nonlesional and
lesional psoriatic skin, being substantially decreased
in lesional psoriatic skin compared with normal
control skin. Immunohistochemical analysis showed
a signi®cant decrease of prosaposin level in the
stratum corneum of psoriatic lesional skin (both in
active-type and in chronic-type plaque) compared
with nonlesional and with normal skin (p < 0.01), and
in psoriatic nonlesional skin compared with normal
control (p < 0.05). Immunolocalization of sphingo-
myelinase in lesional and nonlesional psoriatic skin
showed a decrease in the level of this enzyme in the
stratum corneum of psoriatic lesional, compared
with nonlesional skin. These results support the con-
cept that disturbance of epidermal barrier function
caused by derangement in ceramide generation can
be crucial for the development of psoriatic skin
diseases. Key words: ceramides/prosaposin/psoriasis. J
Invest Dermatol 116:394±400, 2001
T
he intercellular space of the stratum corneum is an
integral part of the epidermal permeability barrier and
is packed with lamellar sheets of lipids as described in
the popular ``brick and mortar'' model (Elias, 1983).
Stratum corneum lipids derive from exocytosis of
lamellar granules into the intercellular space and are important
factors preventing transepithelial permeation of water and of water
soluble material (Landmann, 1988; Wertz, 1992). They mainly
consist of ceramides, and to a lesser extent of free cholesterol,
cholesterol sulfate, and free fatty acids (Wertz et al, 1987).
Ceramides represent a unique, heterogeneous group of at least six
different ceramides (CER 1±6) that differ from each other in the
architecture of the polar head group and in the length of the
nonpolar fatty acid chains (Wertz and Downing, 1983; Wertz et al,
1985; Kerscher et al, 1991). Ceramides have shown to be critical in
epidermal permeability barrier homeostasis (Holleran et al, 1991).
There are two main pathways for ceramide generation. One is
represented by the degradation of glucosyl-ceramides, catalyzed by
b-glucocerebrosidase, and the other by the hydrolysis of sphingo-
myelin (SM) catalyzed by sphingomyelinase (SMase). Both the
early activation of SMase and the later degradation of glucosyl-
ceramides is essential for skin barrier repair (Holleran et al, 1994;
Jensen et al, 1999). The lysosomal degradation of various
glicosphingolipids also require the presence of nonenzymatic
cofactors, the saposins (SAP) or so-called sphingolipid activator
proteins, four of which (SAP A-D) derive from a common
precursor, prosaposin (pSAP), by proteolytic cleavage and glyco-
sylation. The structure, function, and distribution of SAP and of
pSAP in mammalian tissues and body ¯uids have been thoroughly
described (Sano et al, 1989; O'Brien and Kishimoto, 1991; Ito et al,
1993; Hiraiwa et al, 1993). SAP A-D, with molecular weight
ranging from 12 to 14 kDa and with homologous structure, are
speci®c activators of different hydrolases (Hiraiwa et al, 1993). The
activity of b-glucocerebrosidase has been shown to be stimulated
by SAP-C (Wilkening et al, 1998), and the activity of acid SMase is
stimulated by SAP-D (Morimoto et al, 1988; Tayama et al, 1993).
Although the major function of both pSAP and SAP consists in the
lysosomal degradation of sphingolipids, they also play a role in
transporting sphingolipids in the extracellular compartment and in
different human secretory ¯uids (Hineno et al, 1991; FuÈrst and
Sandhoff, 1992). Decreased levels of pSAP have been detected in
the skin of patients with atopic dermatitis, suggesting a role for
pSAP in skin barrier disorders (Chang-Yi et al, 1997). The role of
pSAP and of mature SAP in the epidermal permeability barrier
formation has been recently described (Doering et al, 1999). The
authors showed that SAP-de®cient mice are characterized by
epidermal accumulation of glucosylceramides and SM paralleled
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by ceramide de®ciency, by alteration of lipids binding to the
corni®ed envelopes, by a thickened stratum lucidum with evidence
of scaling, and, lastly, by abnormality in lamellar membrane
maturation.
Psoriasis is a benign in¯ammatory hyperproliferative disease,
presenting an abnormal stratum corneum and a defective skin
barrier function. Comparative studies with normal human skin
have shown progressive increase in transepidermal water loss
(TEWL) in the lesional skin of psoriatic patients with increasing
severe phenotypes (Ghadially et al, 1996), despite a preservation of
the electrolyte barrier (Grice et al, 1973). An ultrastructural analysis
of the stratum corneum of psoriatic lesions has revealed extremely
narrow intercellular spaces between a large number of parakeratotic
corneocytes containing few pathologic epidermal lipids lamellae
(Fartasch, 1997). These morphologic ®ndings are consistent with
biochemical studies that showed a decrease in relative free fatty acid
content and a different pattern in ceramide distribution in psoriatic
plaques, compared with normal control skin (Motta et al, 1993,
1994b). In order to investigate whether the alterations in barrier
function seen in psoriatic skin diseases could be related to
disturbances in the pathways of ceramides generation, in this study
we chose to focus on the activator protein system; we quanti®ed
both the reverse transcriptase±polymerase chain reaction (RT-
PCR) products and the protein expression of pSAP in normal skin
and in lesional and nonlesional psoriatic epidermis. Because pSAP
expression seems to be correlated with epidermal SM content
(Doering et al, 1999), and because acid SMase has been shown to be
important in skin permeability barrier repair (Jensen et al, 1999), we
furthermore localized acid SMase by immunohistochemistry and
compared its protein expression in lesional and nonlesional psoriatic
skin.
MATERIALS AND METHODS
Patients and materials Fresh skin tissue biopsies were obtained from
the lesional skin of patients with psoriasis vulgaris (n = 8, two females and
six males, with age ranging from 30 to 68 y, with a mean of 54 y). Three
male patients among the aforementioned group (age ranging from 30 to 45
y, with a mean of 37 y) donated both lesional and nonlesional skin. Normal
control skin (n = 8) was obtained from uninvolved areas of surgical tumor
resections (basalioma, keratoma).
All specimen underwent a histopathologic examination after routine
hematoxylin and eosin (H&E) staining and the additional immunohisto-
chemical detection of phospholipase A2, type II, was used to grade the
severity of the psoriatic lesions (Ragaz and Ackerman, 1979; Andersen et al,
1994). The histopathologic examination of the psoriatic skin tissue sections
stained with H&E followed by the localization of PLA2, type II, revealed
that four of them were typical examples of ``active plaque'' psoriasis and
four of them of ``chronic plaque'' psoriasis. ``Active plaque'' psoriasis was
characterized by a greater in®ltration of in¯ammatory cells and a higher
number of PLA2, type II-positive ®broblasts in the dermis.
All chemicals were purchased from Sigma (Deisenhofen, Germany),
unless otherwise speci®ed.
Isolation of mRNA The mRNA was isolated from the specimens
obtained from both lesional and nonlesional areas of the three male patients
mentioned above with ``active plaque'' psoriasis vulgaris, and from one
normal control subject. Three additional samples were obtained from the
same patients by simply scraping off the psoriatic lesions. For RNA
isolation, the biopsies were washed in phosphate buffered saline (PBS) and
digested in 0.5% dispase solution for 2 h at 37°C. Then the epidermis was
mechanically separated, frozen in liquid nitrogen, and stored at ±70°C. The
epidermis was harvested in solution buffer (supplied by QuickPrepq
mRNA, Pharmacia, Uppsala, Sweden) and sonicated for 10 s to destroy the
cell membranes without degrading the nucleic acids. Further isolation was
performed in three steps following the suppliers protocol (Pharmacia). After
ethanol precipitation the harvested mRNA was diluted in 50 ml H2O
aliquots.
RT-PCR For reverse transcription mRNA probes were diluted in 11 ml
H2O and heated together with 0.5 mg oligo (dt)12±18-primer at 70°C for
10 min. The RT-reaction was performed at 42°C in 20 mM Tris-HCl,
pH 8.4, 50 mM KCl, 2.5 mM MgCl2, 0.01 M DTT, 1 mM dNTP mix and
200 U SUPERSCRIPT II RT (Gibco BRL, Eggenstein, Germany) for
60 min and stopped at 70°C for 15 min. To nick the mRNA-strand, the
sample was incubated with 2 IU RNAse H (Gibco BRL) for 20 min at
37°C.
For each experiment, primer concentrations, RNA amounts, and PCR
cycles were titrated to establish standard conditions. The validity of
quantitative comparisons of PCR products was insured by using a number
of PCR cycles mapped to, within the linear curve. For PCR, 1 ml to 3 ml of
the sample was incubated in 20 mM Tris-HCl, pH 8.4, 50 mM KCl,
1.5 mM MgCl2, 200 mM dNTP mix, and 0.2 pmol of pSAP and GAPDH
primers (see below). The thermal pro®le used on a Hybaid Limited
TouchDown Thermal Cycler (Hybaid, Middlesex, U.K.) consisted on
denaturation at 94°C for 45 s, annealing at 53°C for 30 s, and an extension
temperature of 72°C for 1 min for 32 cycles. By optimized conditions, the
PCR runs were repeated on the same RNA samples to assure the
reproducibility of the data.
Oligonucleotides used for PCR The oligonucleotides used were
chosen overlapping introns, to avoid the ampli®cation of genomic DNA.
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as internal
control.
GAPDH sense, 5¢-GGTGAAGGTCGGAGTCAACGGA-3¢;
GAPDH antisense, 5¢-GAGGGATCTCGCTCCTGGAAGA-3¢;
pSAP sense, 5¢-GCCTGCACTGACCGTTCACGTG-3¢;
pSAP antisense, 5¢-GGCTCCAATTTTCAAGCACACG-3¢.
Quanti®cation of RT-PCR products PCR reactions were separated
by gel electrophoresis on 2% agarose gels stained with 0.4 mg ethidium
bromide per ml. The gels were visualized over an on-line UV light source
transilluminator (Gel Doc 1000 Video documentation system, Bio-Rad,
Hercules, CA). The PCR products of the expected size (265 bp for
prosaposin and 430 bp for GAPDH) were then manually de®ned and the
bands intensity was quanti®ed using Quantity One quantitation software
(Bio-Rad, Hercules, CA). The intensity of the PCR bands of pSAP were
expressed normalized to GAPDH.
Immunohistochemistry For the immunohistochemical study, all
biopsies of psoriatic lesional, nonlesional, and of normal control skin
were snap frozen in liquid nitrogen for cryostat sectioning. Frozen tissue
samples were submerged in Optimum Cutting Temperature embedding
compound (OCT, Tissue-Tek, Miles Laboratory, Elkhart, IN) and cryostat
sections (6 mm) were prepared on positively charged slides and allowed to
air-dry. Tissue ®xation was obtained with fresh 2% paraformaldehyde in
phosphate-buffered saline (PBS), for 5 min, and methanol, for 10 min at
4°C. Part of the biopsies were ®xed by immersion in 3.7% formaldehyde in
PBS at 4°C for 4 h, and embedded in paraf®n, using an automatic apparatus
(Tissue-TEK VIP, Miles Scienti®c). The melted wax temperature did not
exceed 56°C. Fixed and embedded tissue blocks were allowed to cool and
were stored in plastic cassettes, ready to be cut. The sections were prepared
on twice-washed polylysine-coated slides, and deparaf®nized.
All tissue sections were further processed for indirect immunohisto-
chemistry with an ABC-based method (Vector Laboratories, Burlingame,
CA). After blocking both endogenous biotin binding sites with sequential
incubations of avidin and biotin, and endogenous peroxidases with 15 min
incubation in methanol/1% H2O2, the sections were subjected to
overnight incubation at 4°C with primary speci®c antibodies anti-
SAP-D, antiphospholipase A2, type II, or control solutions. Tissue sections
obtained from the involved and uninvolved psoriatic skin of three patients
were additionally stained with primary speci®c antibody anti-SMase.
Rabbit polyclonal antibodies against SAP-D and human acid SMase
were generously donated by Dr. T. Tezuka, Department of Dermatology
of the Kinki University School of Medicine, Osaka, Japan (Chang-Yi et al,
1997). The antiserum was diluted 1:1000 and 1:2000 for anti-SAP-D and
for anti-SMase, respectively. Monoclonal antibodies against phospholipase
A2, type II, were purchased from Boehringer Mannheim (Mannheim,
Germany). The working concentration of 10 mg per ml showed best results.
As a positive control, a monoclonal anticytokeratin PAN antibody
(Boehringer Mannheim) was used at a concentration of 10 mg per ml.
Negative controls included use of buffer alone or dilutions of nonspeci®c
puri®ed rabbit and mouse IgG in the primary layer (Vector Laboratories,
Burlingame, CA). Antibodies were diluted in 0.1% bovine serum albumin
(BSA) and 0.1% sodium azide (Roth, Karlsruhe, Germany) in PBS
(pH 7.4).
Speci®c binding was detected using a biotin-conjugated horse antimouse
and antirabbit IgG, avidin-biotin peroxidase complex (Vector
Laboratories), and a substrate solution of H2O2 (0.03%) and diamino-
benzidine (2 mg per ml) in 0.5 M Tris-saline, pH 7.6, with 1 M imidazole
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(Roth, Karlsruhe, Germany) and 0.3% sodium azide (Roth). The slides
were then counterstained with hematoxylin, dehydrated through graded
ethanols and xylene, mounted, and coverslipped.
Densitometric analysis and statistics A densitometric analysis of the
stratum corneum immunoreactivity with antisaposin-D of all high quality
samples, in which the stratum corneum was not damaged during tissue
preparation procedures [psoriatic lesional (n = 7), nonlesional (n = 3), and
normal control skin (n = 8)] was used as an alternative of the widely used
scoring method. The analysis was performed in a blinded fashion. Three
images from each tissue section (together covering about 80%±90% of the
tissue section) were randomly selected, recorded with a camera, and
converted to digital ®les (Overlay Framegrubber, Imaging Technology,
Wobuln, MA). The camera (CCD-Kamera VS 450, Stemmer Imaging,
Puchheim, Germany) was within 10% equally sensitive to all wavelengths
in the whole visible spectrum, where the absorption peak of oxidized
diaminobenzidine, used as substrate in the immunohistochemical study, is
465 nm (Fahimi and Herzog, 1973). Three densitometric measurements
normalized to identical surface area of the stratum corneum were
performed per each recorded image using Optimas 6 software (Optimas
Corporation, Bothell, Washington; HTTP://www.optimas.com). This
software analyses digitized gray values and provides a quantitative
measurement of the immunoreactivity in terms of active pixels in the
selected areas, and the number recorded represents the mean density
enclosed by the selected areas, where white is 0 and black is 255. To
quantify the interference of the counterstained parakeratotic nuclei, a
densitometric analysis on parallel sections stained with nonspeci®c antibody
(negative control) and counterstained has been performed.
For statistical evaluation, one-way analysis of variance (ANOVA) with
repeated measures and posthoc pairwise comparisons (ScheffeÂ test) were
used. Data were expressed as mean 6 SEM. A p value below 0.05 was
considered to be signi®cant.
RESULTS
The expression of pSAP is decreased in psoriatic skin The
separation of pSAP and GAPDH RT-PCR products by gel
electrophoresis and ethidium bromide staining showed a
progressive decrease in the expression of pSAP mRNA in the
nonlesional (a) and lesional (b) skin of psoriatic patients (P1, P2,
P3), compared with control (C) (Fig 1). The semiquantitative
assessment of the RT-PCR bands are represented normalized to
GAPDH expression (Fig 2). Obvious is the progressive decrease of
pSAP expression in the nonlesional and in the lesional skin of
Figure 1.Gelelectrophoresis of pSAP RT-PCR products. Gelelectro-
phoresis of GAPDH (upper lanes) and pSAP (lower lanes) in normal control
skin (C), and in three psoriatic patients (P1, P2, P3, uninvolved skin (a),
and involved skin (b)). Total cellular RNA was isolated from epidermal
specimen, and after PCR, reaction products were visualized after
electrophoresis of ethidium bromide-stained agarose gel as described (see
Materials and Methods).
Figure 2. Semiquantitative analysis of pSAP PCR bands. Relative
density levels of pSAP PCR bands are expressed in percentage of GAPDH.
C = Normal control skin; P1, P2, P3 = three psoriatic patients, uninvolved
skin left, involved skin right. Densitometric values obtained from the
corresponding ethidium bromide-stained PCR reaction products in Fig 1
are presented.
Figure 3. Immunohistochemical localization of pSAP-like protein
and nonprimary negative control in normal control skin. (a) pSAP-
like protein; (b) nonprimary negative control. The immunohistochemical
study was performed using the ABC method (see Materials and Methods).
pSAP-like protein was localized as dotty reaction in all epidermal layers, but
especially in the granular-corneocyte transition zone and in the stratum
corneum (a, arrow). No stain was detected using a nonspeci®c primary
antibody (b). Scale bar: 30 mm.
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psoriatic patients compared with control. The densitometric values
of pSAP-expression in lesional psoriatic skin are consistently lower
compared with control.
The three samples obtained by simply scraping off the psoriatic
lesions resulted in nonsigni®cant PCR bands (data not shown).
The amount of pSAP-like protein is signi®cantly decreased
in the stratum corneum of psoriatic skin All samples
investigated showed a very similar pattern of immunoreactivity,
therefore representative samples are shown (Figs 3±5). In normal
control skin, pSAP-like protein was localized as spotty reactions
throughout all the epidermal layers, but most abundantly in the
granular-corneocyte transition zone and in the stratum corneum
(arrow). Also dermal ®broblasts, mast cells, and mononuclear cells
stained intensively (Fig 3a). The negative control showed no stain
(Fig 3b). In psoriatic nonlesional skin, the immunolocalization of
pSAP-like protein was similar to control skin, and it was present
both in the granular-corneocyte transition zone and in the stratum
corneum (arrows), although it was less abundant (Fig 4a). In
lesional psoriatic skin, spotty reactions of pSAP-like protein were
still immunohistochemically detectable at the granular-corneocyte
transition zone (arrow), but a marked decrease of pSAP-like protein
was evident in the stratum corneum (Fig 4b). There was no
difference in the level of pSAP-like protein between the patients
with ``active type'' and ``chronic type'' psoriasis. Dermal
in¯ammatory cells and ®broblasts maintained their labeling with
anti-SAP-D (Fig 4b, small arrow). Quanti®cation of pSAP-like
Figure 4. Immunohistochemical localization of pSAP-like protein
in psoriatic epidermis. In nonlesional psoriatic epidermis (a) pSAP-like
protein is visible in the granular-corneocyte transition zone and in the
lower stratum corneum (arrows). In lesional psoriatic epidermis (b) pSAP-
like protein is decreased in whole epidermis, but especially in the stratum
corneum. Spotty reaction are con®ned to the granular-corneocyte
transition zone (arrow). Positive staining of an in¯ammatory cell in the
dermis is also evident (small arrow). Scale bar: 30 mm.
Figure 5. Immunohistochemical localization of SMase in psoriatic
epidermis. SMase was immunohistochemically detected in tissue sections
of nonlesional and lesional psoriatic skin using the ABC method (see
Materials and Methods). In nonlesional psoriatic skin (a) SMase can be
visualized in the periphery of and weakly within the cells of stratum
spinosum, stratum granulosum, lucidum, and stratum corneum (arrow),
being absent in the stratum basale (small arrow). In lesional psoriatic
epidermis (b) SMase is localized as dotty reactions in the granular-
corneocyte transition zone (arrow). Scale bar: 30 mm.
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immunoreactivity by densitometric analysis of the stratum corneum
of normal control skin, psoriatic nonlesional, and psoriatic lesional
skin showed that in psoriatic lesional skin the level of pSAP-like
protein was signi®cantly lower compared with control and with
psoriatic nonlesional skin (p < 0.01, Table I). The data furthermore
indicated that the level of pSAP-like protein is decreased also in the
stratum corneum of psoriatic nonlesional skin with respect to the
normal control group (p < 0.05, Table I). The intersubject
variation of the psoriatic nonlesional group was higher compared
with the other samples, although all three samples investigated in
this group showed lower expression of pSAP-like protein in the
stratum corneum compared with normal control skin, and higher
expression compared with psoriatic lesional skin. The densitometric
analysis of the stratum corneum of psoriatic lesional skin stained
with nonspeci®c primary antibody and counterstained with
hematoxylin showed no statistical difference to the parallel
sections stained with SAP-D antibody (Table I). This result
demonstrates the low interference of the parakeratotic nuclei
counterstain in the densitometric evaluation.
SMase in the nonlesional skin of psoriatic patients was
immunohistochemically detectable in the cell periphery of the
stratum spinosum, granulosum, and lucidum, and within the
stratum corneum (arrow), being absent in the stratum basale (small
arrow) (Fig 5a). In the lesional skin of psoriatic patients, the
immunolocalization of SMase was mostly decreased in the stratum
corneum, being present as abundant dotty reactions in the granular-
corneocyte transition zone (arrow) (Fig 5b). In addition, dermal
in¯ammatory cells showed a weak staining with anti-SMase.
DISCUSSION
The results of our study show that the mRNA level of pSAP and
the protein level of pSAP-like molecule is signi®cantly decreased in
the lesional epidermis of patients with psoriasis vulgaris (in both the
active-type and the chronic-type plaque) compared with normal
skin and with psoriatic nonlesional skin. Because of the dif®culty in
recruiting psoriatic patients ready to donate tissue biopsies also in
noninvolved body areas, in this study the size of the psoriatic
nonlesional group is very limited. This probably causes the higher
intersubject variation in the densitometric analysis of the pSAP
immunostaining in this group, compared with the other groups.
Also the mRNA study was performed on this limited number of
patient samples. Consequently, the PCR runs were repeated for the
same samples, to assure the validity of the data. Our results of the
samples obtained by scraping off the psoriatic lesions, showing no
signi®cant GAPDH and pSAP PCR bands, demonstrate that
parakeratotic nuclei do not contain suf®cient RNA to in¯uence the
results. This is in accordance with the ®nding of solely condensed
DNA and RNA in the parakeratotic cells in psoriasis, presumably
without metabolic function (Suzuki et al, 1980). The immuno-
histochemical study shows that pSAP-like protein is present in all
epidermal layers, but especially in the granular-corneocyte transi-
tion zone and in the stratum corneum. It is likely that the antibody
recognizes the SAP protein at different maturation stages (from the
preproSAP to mature SAP-D), explaining the localization of the
immunoreactivity in all epidermal layers. pSAP-like protein is
decreased in the stratum corneum of nonlesional psoriatic skin, in
comparison with control, but due to the low number of the
nonlesional psoriatic skin samples, the results of the densitometric
analysis reach a lower signi®cance level. In psoriatic lesional skin,
pSAP-like protein was decreased in all epidermal layers, but
especially in the granular-corneocyte transition zone and in the
stratum corneum. The immunohistochemical evaluation of SMase
in psoriatic skin showed that also SMase, at the protein level, is
decreased in the stratum corneum of lesional, compared with
nonlesional psoriatic skin.
In our study we focused on pSAP, the common precursor of all
SAP, which are known important players in the homeostasis of
ceramides. The main pathway of ceramide generation is considered
to be the hydrolisis of glucosylceramides, mediated by b-gluco-
cerebrosidase. The activity of this enzyme has been shown to be
stimulated by SAP-C (Wilkening et al, 1998). Ceramides are
furthermore generated by hydrolisis of SM, reaction catalyzed by
acid SMase, which seem crucially involved in early cutaneous
barrier repair (Jensen et al, 1999). The activity of this enzyme is
speci®cally stimulated by SAP-D (Morimoto et al, 1988; Tayama
et al, 1993). SAP-D also stimulates acid ceramidase and therefore
functions as an important modulator of the in vivo tissue
concentration of ceramides (Azuma et al, 1994; Klein et al, 1994).
Psoriasis is a skin disease characterized by epidermal hyper-
proliferation and in¯ammation, leading to the formation of a very
thick stratum corneum, up to 10 times thicker than normal;
psoriatic stratum corneum lacks water retention capacity and is
characterized by abnormal cohesiveness. The increase in TEWL in
involved psoriatic epidermis has been well documented (Marks et al,
1981; Tagami and Yoshikuni, 1985; Serup and Blichmann, 1987).
Also hydration by bound water in the psoriatic lesions appears to be
inferior to control skin (Takenouchi et al, 1986). An in vivo study of
skin hydration and water retention capacity in uninvolved skin of
psoriatic patients showed that in nonlesional psoriatic skin TEWL
and water content did not differ from control subjects, and only
water retention capacity differed slightly from controls (Berardesca
et al, 1990). Both barrier and water retention properties require
sphingolipids, comprised by a heterogeneous class of ceramides and
glucosylceramides, and their removal causes an increase in water
loss (Grubauer et al, 1989).
Some ceramides have a known particular function in preventing
the excess water loss. Ceramide 1, for example, containing linoleic
acid ester-linked to a long chain w-hydroxy fatty acid, seems to
have a critical function in the molecular arrangement of the stratum
corneum lamellar lipid bilayer formation (Bouwstra et al, 1998), and
in the assembly and organization of the intercellular space of the
stratum corneum (Wertz and Downing, 1983; Bowser et al, 1985).
Other ceramides characterized by fatty acid and sphingosine chains
of varying size are covalently bound to involucrin and other
structural proteins of corni®ed cell envelopes in terminally
differentiated keratinocytes and form a hydrophobic milieu on
the surface of the cell (Marekov and Steinert, 1998). Psoriatic
plaques showed decreased linoleic acid-esteri®ed ceramides (cer-
amide 1), and ceramides containing phytosphingosine (ceramide 3,
6I, 6II) compared with normal control skin, and increased
ceramides containing sphingosine (ceramides 2I + two new cer-
amide fractions, named ceramide 2II and 5I) (Motta et al, 1993,
1994a). The authors have speculated that the relative decrease in
phytosphingosine-containing ceramides and increase in sphingo-
Table I. Densitometric analysis of skin stratum corneum
following immunostaining with antisaposin D and with
nonspeci®c IgG primary antibodies
Skin samples nc Meand SEM
Normal controla 8 178.02 14.4
Psoriatic nonlesionala 3 124.22* 30.8
Psoriatic lesionala 7 12.14** 2.5
Psoriatic lesionalb 7 5.69**§ 0.8
a, bTissue samples were analysed following immunostaining either with anti
saposin-D antibody (a) or with nonspeci®c rabbit IgG (negative control, b) using
the ABC method, then counterstained with hematoxylin.
cEach n represents the number of skin samples assessed. Each sample was
represented by nine measurements (see Materials and Methods).
dA densitometric analysis of the stratum corneum was performed using Optimas
6 software. The number represents the mean density enclosed by the area of
interest, where white is 0 and black is 255.
**p < 0.01 versus normal control and versus psoriatic nonlesional skin (one-way
ANOVA with posthoc ScheffeÂ test).
*p < 0.05 versus control (one-way ANOVA with posthoc ScheffeÂ test).
§No statistical difference versus psoriatic lesional a(one-way ANOVA with posthoc
ScheffeÂ test).
398 ALESSANDRINI ET AL THE JOURNAL OF INVESTIGATIVE DERMATOLOGY
sine-containing ceramides in the psoriatic scale could derive from
deranged water bioavailability, caused by the excess water loss
occurring in psoriatic scales, compared with normal stratum
corneum. The decrease in ceramide 1 can cause alterations in the
molecular organization of the stratum corneum.
The decreased concentration of pSAP in psoriatic skin could
have consequences for both pathways of ceramide generation. First,
the lack of pSAP/saposin affects the postsecretory processing of
glucosylceramides to ceramides; furthermore, the hydrolysis of the
more hydrophobic glucosylceramides, which contain ester-linked
fatty acids, w-OH fatty acids, and sphingosine requires SAP-C
(Doering et al, 1999). A decrease in pSAP could then provoke a
decrease in ceramide 1, which was observed in psoriatic plaques.
Interestingly, the most polar ceramides, which contain a-OH fatty
acids and sphingosine, were found to be elevated in the absence of
pSAP in pSAP±/± mice (Doering et al, 1999), and these ceramides
have been shown to be elevated in psoriatic lesional skin (Motta
et al, 1993, 1994a). This suggests a compensatory capacity of
sphingolipid biosynthesis pathways in keratinocytes lacking pSAP/
SAP. Accumulation of more hydrophilic ceramide species can
affect the coherence of the stratum corneum. In pSAP±/± mice an
increased epidermal SM concentration was reported (Doering et al,
1999). This may suggest that SAP can play a role in regulating
SMase activity. Because epidermal SM contains signi®cant quantity
of a-OH ceramides, the elevated a-OH ceramide species observed
in psoriatic skin could also re¯ect an increase in SM-dependent
hydrolysis. The importance of the conversion of SM to ceramides
by acid SMase in barrier function has recently been demonstrated
(Jensen et al, 1999). The authors showed that the activity of acid
SMase, localized in the outer epidermal layers, increases after barrier
disruption; this increase is paralleled by SM degradation, and by the
production of ceramides. They furthermore showed that experi-
mental inhibition of acid SMase results in delayed permeability
barrier repair. Their results are in accordance with studies on
patients characterized by acid SMase de®ciency, where by
experimental disruption of the permeability barrier a delayed repair
process was observed (Schmuth et al, 1999). We showed a
decreased concentration of acid SMase in the upper epidermal
layers in psoriatic lesional, compared with nonlesional skin. SMase
was present abundantly only in the granular-corneocyte transition
zone. The decrease of SMase can have consequent alterations in
skin barrier function.
Apart from the importance of ceramides as structural
component of stratum corneum lipids, there is an additional
aspect in ceramides function that can be taken into account.
Ceramides generated by SM hydrolysis have been shown to be
involved in programmed cell death (Obeid et al, 1993), and
furthermore in the regulation of keratinocyte proliferation and
differentiation in vitro (Bielawska et al, 1992; Geilen et al, 1997).
The induction of the SM cycle and ceramide production by
calcipotriol (a vitamin D3 analog) and its antiproliferative effect
in vitro have been investigated in sight of its application in the
treatment of psoriasis (Geilen et al, 1996). The closed relation
between skin permeability barrier dysfunction and epidermal
hyperplasia was also described (Proksch et al, 1993). We can
speculate that the alteration in skin ceramides, produced by
derangement in their pathways of synthesis and degradation, can
affect both keratinocyte proliferation and skin barrier function,
both aspects being relevant in the pathogenesis of psoriasis. It
was furthermore hypothesized that disturbances of the epidermal
barrier function could also act as initiator of a cascade that
subsequently triggers an in¯ammatory response in the dermis,
contributing to the development of psoriatic lesions (Elias et al,
1993; Nickoloff and Naidu, 1994). The link between skin
barrier dysfunction, keratinocyte hyperproliferation, and in¯am-
matory response is supported by occlusion studies, which have
shown a bene®cial effect by reducing the size and the epidermal
hyperplasia of most psoriatic lesions (Petzold et al, 1970; Shore,
1985; Friedman, 1987).
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